@article{ref1,
title="Pharmacotherapy may attenuate the risk of child abuse in attention-deficit/hyperactivity disorder from the real-world evidence",
journal="Journal of child and adolescent psychopharmacology",
year="2023",
author="Lin, Cian-Cian and Chung, Chi-Hsiang and Chien, Wu-Chien and Tzeng, Nian-Sheng",
volume="33",
number="2",
pages="59-68",
abstract="OBJECTIVE: Psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD), may serve as a risk factor for child abuse. <br><br>METHODS: This study aimed to evaluate the association between children and adolescents with ADHD diagnosis and the risk of child abuse. The effectiveness of a pharmacological intervention on reducing the risk of child abuse was also assessed. A nationwide, population-based, retrospective with a matched-cohort study design was used. Data were from the National Health Insurance Research Database of Taiwan over a 15-year period (2000-2015). <br><br>RESULTS: Increased risk of child abuse in the ADHD group was noticed and the adjusted hazard ratio (HR) was 1.797 (95% confidence interval [CI] = 1.245-2.388, p < 0.001). The Kaplan-Meier analysis showed a significantly higher cumulative incidence in the ADHD group over the 15-year period (Log-rank test p < 0.001). ADHD patients with other psychiatric comorbidities had a higher risk of child abuse. Pharmacological treatment of either methylphenidate or atomoxetine was associated with a reduced risk of child abuse. The total adjusted HR was 1.466 (95% CI = 1.077-1.883, p < 0.001) in medicine group compared with the controls. <br><br>CONCLUSIONS: ADHD was associated with a subsequent risk of child abuse in Taiwan. Pharmacological treatment could reduce the risk of child abuse in ADHD patients.<p /> <p>Language: en</p>",
language="en",
issn="1044-5463",
doi="10.1089/cap.2023.0003",
url="http://dx.doi.org/10.1089/cap.2023.0003"
}